These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 25967234)

  • 1. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis.
    Wu B; Sun C; Feng F; Ge M; Xia L
    J Exp Clin Cancer Res; 2015 May; 34(1):44. PubMed ID: 25967234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
    Dahlrot RH
    Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis.
    Han M; Guo L; Zhang Y; Huang B; Chen A; Chen W; Liu X; Sun S; Wang K; Liu A; Li X
    Mol Neurobiol; 2016 Jan; 53(1):720-727. PubMed ID: 25589004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.
    Zhang M; Song T; Yang L; Chen R; Wu L; Yang Z; Fang J
    J Exp Clin Cancer Res; 2008 Dec; 27(1):85. PubMed ID: 19108713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of CD133 and nestin in patients with glioma: a population-based study.
    Dahlrot RH; Hansen S; Jensen SS; Schrøder HD; Hjelmborg J; Kristensen BW
    Int J Clin Exp Pathol; 2014; 7(7):3739-51. PubMed ID: 25120750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the clinical value of cancer stem cell markers in gliomas?
    Dahlrot RH; Hermansen SK; Hansen S; Kristensen BW
    Int J Clin Exp Pathol; 2013; 6(3):334-48. PubMed ID: 23412423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlative study of distribution of brain tumor stem cell with micro-vascular system].
    Li MW; Niu CS
    Zhonghua Yi Xue Za Zhi; 2010 Feb; 90(5):305-9. PubMed ID: 20368050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-expression of putative cancer stem cell markers, CD133 and Nestin, in skin tumors.
    Sabet MN; Rakhshan A; Erfani E; Madjd Z
    Asian Pac J Cancer Prev; 2014; 15(19):8161-9. PubMed ID: 25339000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the stem cell markers CD133 and nestin in pancreatic ductal adenocarcinoma and clinical relevance.
    Kim HS; Yoo SY; Kim KT; Park JT; Kim HJ; Kim JC
    Int J Clin Exp Pathol; 2012; 5(8):754-61. PubMed ID: 23071857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells.
    Barrantes-Freer A; Renovanz M; Eich M; Braukmann A; Sprang B; Spirin P; Pardo LA; Giese A; Kim EL
    PLoS One; 2015; 10(6):e0130519. PubMed ID: 26086074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis.
    Cheng B; Yang G; Jiang R; Cheng Y; Yang H; Pei L; Qiu X
    Oncotarget; 2016 Oct; 7(40):65862-65875. PubMed ID: 27588469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD133 is a marker of bioenergetic stress in human glioma.
    Griguer CE; Oliva CR; Gobin E; Marcorelles P; Benos DJ; Lancaster JR; Gillespie GY
    PLoS One; 2008; 3(11):e3655. PubMed ID: 18985161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis.
    Wu H; Qi XW; Yan GN; Zhang QB; Xu C; Bian XW
    PLoS One; 2014; 9(6):e100168. PubMed ID: 24940615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nestin Expression Is Associated with Poor Clinicopathological Features and Prognosis in Glioma Patients: an Association Study and Meta-analysis.
    Lv D; Lu L; Hu Z; Fei Z; Liu M; Wei L; Xu J
    Mol Neurobiol; 2017 Jan; 54(1):727-735. PubMed ID: 26768429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis.
    Ma YC; Yang JY; Yan LN
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1007-16. PubMed ID: 23478672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship among integrin alpha 7, CD133 and Nestin as well as their correlation with clinicopathological features and prognosis in astrocytoma patients.
    Li C; Liu J; Yang W; Chen C; Wu B
    Clin Neurol Neurosurg; 2022 Jun; 217():107198. PubMed ID: 35430343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pathological characteristics of glioma stem cell niches.
    He H; Li MW; Niu CS
    J Clin Neurosci; 2012 Jan; 19(1):121-7. PubMed ID: 22178090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis.
    Zhong C; Wu JD; Fang MM; Pu LY
    Tumour Biol; 2015 Sep; 36(10):7623-30. PubMed ID: 25921286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.
    Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC
    Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
    Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
    Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.